Survey of Ophthalmology
Volume 45 , Pages S284-S289 , May 2001

Efficacy and Safety of Memantine, an NMDA-Type Open-Channel Blocker, for Reduction of Retinal Injury Associated with Experimental Glaucoma in Rat and Monkey

References 

  1. Brooks DE, Garcia GA, Dreyer EB, et al.  Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res. 1997;58:864–867
  2. Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells (uncompetitive antagonism). J Physiol (Lond). 1997;499:27–46
  3. Chen HS, Pellegrini JW, Aggarwal SK, et al.  Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine (therapeutic advantage against NMDA receptor-mediated neurotoxicity). J Neurosci. 1992;12:4427–4436
  4. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung. 1991;41:773–780
  5. Dreyer EB, Zurakowski D, Schumer RA, et al.  Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299–305
  6. Gaasterland D, Kupfer C. Experimental glaucoma in the rhesus monkey. Invest Ophthalmol. 1974;13:455–457
  7. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung. 1992;42:904–913
  8. Gu Z, Yamamoto T, Kawase C, et al: [Neuroprotective effect of N-methyl-D-aspartate receptor antagonists in an experimental glaucoma model in the rat]. Nippon Ganka Gakkai Zasshi 104:11–6, 2000
  9. Hare W, Ton H, WoldeMussie E, et al.  Electrophysiological and histological measures of retinal injury in chronic ocular hypertensive monkeys. Eur J Ophthalmol. 1999;9(Suppl):30–33
  10. Hare W, Ton H, Ruiz G, et al.  Characterization of retinal injury using ERG measures obtained with both conventional and multifocal methods in chronic ocular hypertensive primates. Invest Ophthalmol Vis Sci. 2001;42:127–136
  11. Hare WA, WoldeMussie E, Feldmann B. Functional measures of inner retinal damage following acute retinal ischemia with and without pretreatment with NMDA antagonists. Invest Opthalmol Vis Sci. 1997;38(Suppl):74;[abstract]
  12. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D- aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett. 1995;195:137–139
  13. Lagreze WA, Knorle R, Bach M, Feuerstein TJ. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci. 1998;39:1063–1066
  14. Osborne NN. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis Neurosci. 1999;16:45–52
  15. Parsons CG, Gruner R, Rozental J, et al.  Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5- dimethyladamantan). Neuropharmacology. 1993;32:1337–1350
  16. Vorwerk CK, Lipton SA, Zurakowski D, et al.  Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37:1618–1624
  17. Winblad B, Poritis N. Memantine in severe dementia (results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)). Int J Geriatr Psychiatry. 1999;14:135–146
  18. Wijono M, WoldeMussie E, Ruiz G. Process of retinal ganglion cell damage by elevated intraocular pressure in rat eyes. Invest Ophthalmol Vis Sci. 1999;40(suppl):672
  19. WoldeMussie E, Ruiz G, Feldmann B. Effect of chronically elevated intraocular pressure on loss of retinal ganglion cells in rats. Invest Ophthalmol Vis Sci. 1997;38(suppl):159

☆ The authors are employed by Allergan, Inc., Irvine, CA, USA.

PII: S0039-6257(01)00200-4

Survey of Ophthalmology
Volume 45 , Pages S284-S289 , May 2001

Article Tools

* Image Usage & Resolution